BioSpace News Archive

aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Company”), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the positive outcome of a Type B End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding its lead therapeutic candidate, efzofitimod (ATYR1923), for the treatment of pulmonary sarcoidosis.

TRACON Pharmaceuticals (Nasdaq: TCON), today announced that the first patient has been dosed following the approval of the amended ENVASARC protocol by the U.S. Food and Drug Administration (“FDA”).

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has submitted a Scientific Advice Briefing Document with the European Medicines Agency (EMA) for QRX003, the Company’s investigational treatment for Netherton Syndrome.

Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), announced today that results from the US Phase 3 pivotal Cardigan I and Cardigan II studies of sofpironium bromide gel, 15% in primary axillary hyperhidrosis patients were selected for an oral presentation at the Late-Breaking Research session during the American Academy of Dermatology’s (AAD) 2022 Annual Meeting.

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, announced that it has appointed Roger Adsett to the Company’s Board of Directors, effective March 8, 2022.

Virios Therapeutics, Inc. announced today that its fourth quarter and full year 2021 financial results will be reported on Thursday, March 17, 2022 before the open of the financial markets.

XOMA Corporation announced today its Chairman and Chief Executive Officer, Jim Neal, will present at Oppenheimer’s 32nd Annual Healthcare Conference (virtual) on Thursday, March 17, 2022, at 12:40 PM ET.

Applied Therapeutics, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2021.

Graybug Vision, Inc. provided an update on recent corporate developments and reported financial results for the full year ended December 31, 2021.

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, March 30, 2022, 5:00 p.m. ET.